Publications by authors named "D Reece"
Article Synopsis
- The study focuses on the use of botulinum toxin, particularly onabotulinum toxin A (OTA), for treating migraine and post-traumatic headache (PTH) in military personnel and veterans.
- The unique challenges faced by this population, including increased pain intensity and longer headache durations due to combat-related trauma, highlight the need for effective headache management strategies.
- The literature review identified 8 relevant studies, mainly from the U.S., indicating that chronic migraine is the most common diagnosis treated with botulinum toxin, suggesting its effectiveness for preventing such conditions in service members.
Background: Young patients ≤ 50 years old with multiple myeloma (MM) account for about 10% of cases and are underrepresented in the literature.
Methods: We explored disease characteristics, treatments, and outcomes following modern therapies of young MM patients using the Canadian Myeloma Research Group (CMRG) database. We included 493 patients ≤ 50 years old diagnosed with MM or plasma cell leukemia without concurrent amyloidosis or POEMS syndrome from January 1, 2010, to July 1, 2022.
Given the early use of triplet and quadruplet regimens, most patients with multiple myeloma (MM) will be exposed and/or refractory to PIs, IMiDs, and anti-CD38 mAbs after first- or second-line treatment. Effective treatment for this group of triple class exposed/refractory (TCE/R) patients is crucial. Here we present a post-hoc subgroup analysis of TCE/R patients treated on the ALGONQUIN study of belantamab mafodotin plus pomalidomide-dexamethasone (belamaf-Pd) for relapsed MM.
View Article and Find Full Text PDFBackground: This prospective longitudinal study compares outcomes for Medicare beneficiaries receiving outpatient percutaneous image-guided lumbar decompression (PILD) using the ® procedure to patients undergoing outpatient laminectomy. All patients were diagnosed with lumbar spinal stenosis (LSS) with neurogenic claudication (NC).
Methods: All medical claims for 100 % of Medicare beneficiaries were reviewed, with study subjects identified using Centers for Medicare and Medicaid Research Identifiable Files.
Article Synopsis
- The study focused on patients with relapsed or refractory multiple myeloma (RRMM) who previously received lenalidomide, examining the effectiveness of a treatment combination involving pomalidomide, daratumumab, and dexamethasone (DPd).
- During the trial, a total of 112 patients were treated, with a median overall survival (OS) of 56.7 months after 41.9 months of follow-up, showing promising results.
- The treatment was generally safe, with adverse events leading to discontinuation in a small percentage of patients, suggesting that this combination therapy could be a viable option for RRMM patients needing further treatment post-lenalidomide.